rs730881709
Variant summary
Our verdict is Pathogenic. The variant received 16 ACMG points: 16P and 0B. PVS1PP5_Very_Strong
The NM_000136.3(FANCC):c.1302dupT(p.Gly435TrpfsTer83) variant causes a frameshift change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000026 in 1,613,728 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Likely pathogenic (★★). Synonymous variant affecting the same amino acid position (i.e. D434D) has been classified as Likely benign. Variant results in nonsense mediated mRNA decay.
Frequency
Consequence
NM_000136.3 frameshift
Scores
Clinical Significance
Conservation
Publications
Genome browser will be placed here
ACMG classification
Our verdict: Pathogenic. The variant received 16 ACMG points.
Transcripts
RefSeq
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|
| FANCC | NM_000136.3 | c.1302dupT | p.Gly435TrpfsTer83 | frameshift_variant | Exon 13 of 15 | ENST00000289081.8 | NP_000127.2 |
Ensembl
Frequencies
GnomAD3 genomes AF: 0.0000197 AC: 3AN: 152176Hom.: 0 Cov.: 33 show subpopulations
GnomAD2 exomes AF: 0.00000399 AC: 1AN: 250858 AF XY: 0.00 show subpopulations
GnomAD4 exome AF: 0.0000267 AC: 39AN: 1461552Hom.: 0 Cov.: 37 AF XY: 0.0000206 AC XY: 15AN XY: 727062 show subpopulations
Age Distribution
GnomAD4 genome AF: 0.0000197 AC: 3AN: 152176Hom.: 0 Cov.: 33 AF XY: 0.00 AC XY: 0AN XY: 74342 show subpopulations
Age Distribution
ClinVar
Submissions by phenotype
Fanconi anemia complementation group C Pathogenic:3
Variant summary: FANCC c.1302dupT (p.Gly435TrpfsX83) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. Truncations downstream of this position have been classified as pathogenic by our laboratory. The variant allele was found at a frequency of 4e-06 in 250858 control chromosomes. c.1302dupT has been reported in the literature in at-least one individual referred for cancer panel testing (Susswein_2016). This report does not provide unequivocal conclusions about association of the variant with Fanconi Anemia Group C. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Three clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. All laboratories classified the variant as pathogenic/likely pathogenic. Based on the evidence outlined above, the variant was classified as likely pathogenic. -
This submission and the accompanying classification are no longer maintained by the submitter. For more information on current observations and classification, please contact variantquestions@myriad.com. -
- -
Fanconi anemia Pathogenic:1
This sequence change creates a premature translational stop signal (p.Gly435Trpfs*83) in the FANCC gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 124 amino acid(s) of the FANCC protein. This variant is present in population databases (rs730881709, gnomAD 0.002%). This variant has not been reported in the literature in individuals affected with FANCC-related conditions. ClinVar contains an entry for this variant (Variation ID: 182467). This variant disrupts a region of the FANCC protein in which other variant(s) (p.Arg548* and p.Leu554*) have been determined to be pathogenic (PMID: 8103176, 8613549, 8829660, 8882868). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic. -
FANCC-related disorder Pathogenic:1
The FANCC c.1302dupT variant is predicted to result in a frameshift and premature protein termination (p.Gly435Trpfs*83). This variant has been reported in a cohort study about next-generation cancer panel testing (Susswein et al. 2016. PubMed ID: 26681312. Table S1). This variant is reported in 0.0016% of alleles in individuals of European (Non-Finnish) descent in gnomAD. Frameshift variants in FANCC are expected to be pathogenic. This variant is interpreted as likely pathogenic. -
not provided Pathogenic:1
Frameshift variant predicted to result in abnormal protein length as the last 124 amino acids are replaced with 82 different amino acids, and other similar variants have been reported in HGMD; Not observed at significant frequency in large population cohorts (gnomAD); Observed in an individual referred for hereditary cancer panel testing (PMID: 26681312); This variant is associated with the following publications: (PMID: 26681312, Gordon2000[Book], 29922827) -
Hereditary cancer-predisposing syndrome Pathogenic:1
The c.1302dupT pathogenic mutation, located in coding exon 12 of the FANCC gene, results from a duplication of T at nucleotide position 1302, causing a translational frameshift with a predicted alternate stop codon (p.G435Wfs*83). This alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at